Research supply · Telehealth · Paid media
Research-supply peptide stores and clinician-led telehealth brands, built end to end. Then we run the paid media this category keeps getting banned from, and keep it running.
Before you spend a dollar on this, it is worth seeing the actual plan on paper. Twenty minutes and it is yours, whether or not you ever hire us.
That last line is the only one you were ever supposed to do.
One client store, research-supply track, every campaign in the account, July 2026. Pulled from the ad platform's own reporting, not a projection.
| Campaign | Spend | Purchases | Value | ROAS | Cost per purchase |
|---|---|---|---|---|---|
| Campaign one | $4,982.16 | 78 | $16,739.06 | 3.36 | $63.87 |
| Campaign two | $1,276.84 | 22 | $3,972.96 | 3.11 | $58.04 |
| Account total | $6,259.00 | 100 | $20,712.02 | 3.31 | $62.59 |
Reporting window July 1 to July 31, 2026. Results are for one operating brand and do not guarantee the outcome of any other account.
These are different businesses with different rules, timelines and buyers. We run both, and we keep them strictly separate. Most founders start with one and add the other later.
A research-supply brand selling to labs and research buyers. Faster to launch, lower capital, no clinician network.
A clinician-led brand where patients complete intake, meet a licensed provider, and receive a prescription. Higher barrier, higher lifetime value.
| Decision factor | RUO store | Telehealth brand |
|---|---|---|
| Prescription required | No | Yes, every order |
| Clinician network | Not applicable | Required in every state you sell |
| Upfront build | Lower | Higher, licensing and credentialing heavy |
| Payment processing | Specialist processors, higher reserves | Standard healthcare processors |
| Paid ad risk | High, most platforms restrict the category | Manageable with policy-reviewed creative |
| Repeat revenue | Reorder driven | Subscription and refill driven |
| Best if you have | Supply relationships and ecommerce instincts | Capital, patience, and a clinical partner |
Every stage is built, staffed and monitored by us. You approve, we operate.
Synthesis partner selection, purity specification, and supply agreements with backup capacity.
Third-party HPLC and mass spec on every batch, with certificates published against lot numbers.
Storefront with research-use labeling, age gating, lot lookup, and processor placement that will hold.
Pick, pack and cold-chain where the material needs it, with reorder flows that bring buyers back.
Branded questionnaire, identity checks and eligibility screening built to your protocol.
Licensed clinicians in all fifty states, scheduled and credentialed on your behalf.
Prescription routing to vetted compounding partners with full documentation.
Cold-chain shipping, refill cadence and retention flows that keep patients subscribed.
Telehealth pathway. Every order is reviewed and prescribed by a licensed clinician.
This is the hardest part of the business and the reason most peptide brands stall out at a few thousand a month in spend. The storefront is a solved problem. Distribution is not.
None of these are copywriting problems. They are category, certification and infrastructure problems, and they are why swapping a headline never fixes a disapproval.
Platforms group them with prescription drugs and unsafe supplements. The restriction attaches to what you sell, not to how you word it.
Google requires LegitScript certification for telemedicine providers and online pharmacies before they can advertise at all. Without it there is no campaign to optimise.
Ads pass, then the crawler reads your site. One dosing table or a weight-loss claim on the page takes the whole account down with it.
A business account restriction can pull down pixels, pages, catalogues and audiences at the same time. You do not lose a campaign, you lose the learning.
Decisions land in hours and are largely automated. Appeals take weeks, and an appeal filed without documentation prepared in advance usually fails.
Chargebacks and disputes feed risk scoring on both sides. A payments problem you ignored in month two shows up as an ads problem in month four.
The work happens before spend, not after a disapproval. That is the whole method.
LegitScript and platform approvals are filed and cleared first. We will not launch a campaign that is going to be switched off in week two.
Each creative and each headline is checked against the live policy text before it runs. Policies move, so approved assets are re-checked, not assumed safe forever.
Claims, labeling and disclosures on the destination page are audited alongside the ad, because that page is what gets crawled.
Assets are separated so a single restriction cannot cascade across pixels, pages and audiences. Isolation is cheap. Rebuilding attribution is not.
Certification records, claim substantiation and policy mapping are assembled before you need them, so an appeal goes out the same day rather than in three weeks.
Spend increases follow account health, not impatience. Most bans happen right after a brand scales into a structure that was never tested at volume.
Most people who call us do not need another storefront. They need the one thing almost nobody will sell them: paid media in a category that gets accounts banned. We run it for telehealth, for research supply, or for both at once.
No build fee and no rebuild. You keep the store, the brand and the supply you already have. We take over the advertising, the policy review behind it and the account architecture that stops one disapproval from taking the rest down.
Google requires LegitScript certification for telemedicine providers and online pharmacies before they are allowed to advertise at all, and Meta restricts prescription promotion to authorised advertisers. Until that paperwork clears there is no campaign to optimise, so most agencies never get past the starting line.
Then the claims review starts. Weight-loss and outcome language is the fastest route to a disapproval, and the landing page gets read as carefully as the ad.
This one is harder, not easier. There is no LegitScript equivalent for research-use-only peptides, so there is no badge to earn and no queue to join. Platforms read the catalogue as unapproved pharmaceuticals, which means the restriction attaches to the product rather than the wording.
Everything has to be won on the parts you control: how the offer is framed, what the destination page claims, and an account structure that survives a review it cannot pre-clear.
What running this well actually means. Agencies quote peptides and then quietly decline. The ones that say yes usually run it like a supplement brand, collect a restriction in week three, and hand the account back. We do this the same way we do everything else: certification first, every asset through policy review, nothing cloaked and no misleading claims. If a product cannot be advertised compliantly we will say so before you pay us, and tell you which parts of the range can carry the spend instead.
Meta, Google and TikTok campaigns built certification-first, reviewed before spend, and structured so one restriction cannot take the account with it. This is the capability the rest of the business depends on.
Licensed providers in all fifty states, credentialed and scheduled under your brand.
Policy review before anything ships.
Identity, packaging and a conversion-tuned store wired to your intake flow.
One dashboard from ad click through consult, script and repeat purchase, so you can see which channel actually pays.
Email and SMS built around refill timing, not calendar blasts.
Vetted compounding partners, cold-chain logistics, and inventory planning tied to real subscriber volume.
One build fee to stand the business up, then a flat monthly to run it. On the research track the monthly does not start until ads are actually running. Already built and only need the advertising? That is $2,499 a month on its own.
| Package | RUO Launch For research-supply brands $3,999build, plus $2,499 per month starting when ads go live |
Telehealth Launch For clinician-led brands. Most common. $6,999build, plus $2,499 per month operating |
Both tracks Research supply plus a prescription arm Customscoped to the states and categories you want |
|---|---|---|---|
| Brand | Brand identity and packaging built for research supply | Brand identity for the telehealth arm | Separate branding built for the RUO and telehealth sides, so the language never blurs |
| Website | Website designed, built and wired into an e-commerce platform so customers can actually check out | Website built, then the doctor funnel wired directly into it | Separate storefronts, creative and compliance review |
| Certification | Not applicable on the research track | LegitScript certification filed and secured, which is what unlocks paid media at all | LegitScript for the prescription arm |
| Clinicians | Not applicable | Doctor network, credentialed and ready to take consults | Two brands operated in parallel and kept legally distinct |
| Pharmacy | Not applicable | Pharmacy network with prescription routing and a full audit trail | Shared supply and fulfilment wherever it is permitted |
| Payments | A payment processor that genuinely accepts peptides, not one that drops you in month two | Payment processor placement that survives the healthcare underwriting review | Both, kept legally distinct |
| Supply | Supply partner sourcing, batch testing and COA hosting | Compounding partners with full documentation | Shared supply and fulfilment wherever it is permitted |
| Fulfilment | Fulfilment handled end to end, from inventory through shipping | Fulfilment handled end to end | Consolidated across both |
| Paid media | Compliant paid media, written for policy review and managed weekly | Compliant paid media across Meta and Google, managed weekly | Consolidated attribution across both |
| Operator | Every operating piece in between, so you are not stitching vendors together yourself | One accountable partner | Dedicated operator on your account |
| Book a 20-minute call | Book a 20-minute call | Book a 20-minute call |
Already built and only need the advertising? That is $2,499 a month on its own, month to month.
Most peptide brands do not fail on product. They fail on a disabled ad account, a payment processor freeze, or a pharmacy that cannot document what it shipped.
Research supply and prescription care follow different rules. Running them under one roof only works if the language, labeling and marketing stay separate. That separation is a deliverable, not an afterthought.
Research use only means research use only. Products sold on an RUO storefront are not drugs, are not for human or veterinary use, and carry no therapeutic claims. If your plan depends on customers using the material themselves, the prescription track is the only route we will build.
Tell us what you want to sell. We will tell you exactly what it takes to launch it legally and profitably, and hand you the blueprint either way.